ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead product, which is in clinical-stage development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase. An additional clinical-stage program includes compounds that activate the cell's DNA damage response mechanism mediated by the E2F-1 transcription factor. The Company's most advanced pre-clinical development programs are focused on compounds that inhibit the Eg5 kinesin spindle protein and the BRAF kinase. ArQule's current discovery efforts are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate), an energy source for cells.
Contact:
Olaf Lamberz
Corporate Communications
Phone +49(0)89-78-08-442
+49(0)172-88-70-153
olaf.lamberz@daiichi-sankyo.eu
Contact: Olaf Lamberz, Corporate Communications, Phone +49(0)89-78-08-442, +49(0)172-88-70-153, olaf.lamberz@daiichi-sankyo.eu
